BREZTRI 9 ug/1

BREZTRI 9 ug/1 is a combination inhaler containing budesonide, glycopyrrolate, and formoterol fumarate. It is designed for respiratory conditions, offering a convenient treatment option for managing symptoms. This metered aerosol inhaler is manufactured by AstraZeneca Pharmaceuticals LP.

BREZTRI 9 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This combination inhaler works by reducing inflammation and relaxing the airways, making it easier to breathe. It is often prescribed for individuals who require both an inhaled corticosteroid and a long-acting bronchodilator. The inhaler is designed to provide consistent dosing for effective symptom management.

Common effects of BREZTRI 9 ug/1 may include throat irritation, hoarseness, and dry mouth. Some users might experience headaches or nausea. These effects are generally mild and temporary. If any side effects persist or worsen, it is important to consult a healthcare provider.

BREZTRI 9 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with a history of severe hypersensitivity to any of the components should avoid using this inhaler. Regular monitoring may be required for individuals with certain underlying health conditions.

BREZTRI 9 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other respiratory depressants should be used with caution while using this inhaler.